Semimechanistic pharmacokinetic/pharmacodynamic model for assessment of activity of antibacterial agents from time-kill curve experiments

Antimicrobial Agents and Chemotherapy

Volumn 51, Issue 1, 2007, Pages 128-136

  Nielsen, Elisabet I ^a,b   Viberg, Anders ^a   Löwdin, Elisabeth ^b   Cars, Otto ^b   Karlsson, Mats O ^a   Sandström, Marie ^a  

^a UPPSALA UNIVERSITY   (Sweden)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ABBOTICIN; ANTIINFECTIVE AGENT; BENSYLPENICILLIN; CEFUROXIME; ERYTHROMYCIN; MOXIFLOXACIN; PENICILLIN G; UNCLASSIFIED DRUG; VANCOMYCIN;

ARTICLE; BACTERIAL COUNT; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; DRUG DEGRADATION; DRUG MECHANISM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STREPTOCOCCUS PYOGENES;

ALGORITHMS; ANTI-BACTERIAL AGENTS; AZA COMPOUNDS; CEFUROXIME; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROMYCIN; MICROBIAL SENSITIVITY TESTS; MODELS, BIOLOGICAL; PENICILLIN G; QUINOLINES; STREPTOCOCCUS PYOGENES; VANCOMYCIN;

EID: 33846024399     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00604-06     Document Type: Article

References (25)

1. Balaban, N. Q., J. Merrin, R. Chait, L. Kowalik, and S. Leibler. 2004. Bacterial persistence as a phenotypic switch. Science 305:1622- 1625.
2. Beal, S. L. 2001. Ways to fit a PK model with some data below the quantification limit. J. Pharmacokinet. Pharmacodyn. 28:481-504.
3. Beal, S. L., and L. B. Sheiner. 1989-;-1998. NONMEM users guides. GloboMax, Inc., Hanover, MD.
4. Craig, W. A. 1995. Interrelationship between pharmacokinetics and pharmacodynamics in determining dosage regimens for broad-spectrum cephalosporins. Diagn. Microbiol. Infect. Dis. 22:89-96.
5. Critchley, I. A., D. F. Sahm, C. Thornsberry, R. S. Blosser-Middleton, M. E. Jones, and J. A. Karlowsky. 2002. Antimicrobial susceptibilities of Streptococcus pyogenes isolated from respiratory and skin and soft tissue infections: United States LIBRA surveillance data from 1999. Diagn. Microbiol. Infect. Dis. 42:129-135.
6. Drusano, G. L. 2004. Antimicrobial pharmacodynamics: critical interactions of 'bug and drug.' Nat. Rev. Microbiol. 2:289-300.
7. Frimodt-Moller, N. 2002. How predictive is PK/PD for antibacterial agents? Int. J. Antimicrob. Agents 19:333-339.
8. Gustafsson, I., E. Lowdin, I. Odenholt, and O. Cars. 2001. Pharmacokinetic and pharmacodynamic parameters for antimicrobial effects of cefotaxime and amoxicillin in an in vitro kinetic model. Antimicrob. Agents Chemother. 45:2436-2440.
9. Jonsson, E. N., and M. O. Karlsson. 1999. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput. Methods Programs Biomed. 58:51-64.
10. Karlsson, M. O., S. L. Beal, and L. B. Sheiner. 1995. Three new residual error models for population PK/PD analyses. J. Pharmacokinet. Biopharm. 23:651-672.
11. Keren, I., N. Kaldalu, A. Spoering, Y. Wang, and K. Lewis. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol. Lett. 230:13-18.
12. Liu, P., K. H. Rand, B. Obermann, and H. Derendorf. 2005. Pharmacokinetic-pharmacodynamic modelling of antibacterial activity of cefpodoxime and cefixime in in vitro kinetic models. Int. J. Antimicrob. Agents 25:120-129.
13. Lorian, V. 1989. In vitro simulation of in vivo conditions: physical state of the culture medium. J. Clin. Microbiol. 27:2403-2406.
14. MacGowan, A., and K. Bowker. 2002. Developments in PK/PD: optimising efficacy and prevention of resistance. A critical review of PK/PD in in vitro models. Int. J. Antimicrob. Agents 19:291-298.
15. Marshall, S., F. Macintyre, I. James, M. Krams, and N. E. Jonsson. 2006. Role of mechanistically-based pharmacokinetic/pharmacodynamic models in drug development: a case study of a therapeutic protein. Clin. Pharmacokinet. 45:177-197.
16. Meagher, A. K., A. Forrest, A. Dalhoff, H. Stass, and J. J. Schentag. 2004. Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob. Agents Chemother. 48:2061-2068.
17. Mouton, J. W., A. A. Vinks, and N. C. Punt. 1997. Pharmacokinetic-pharmacodynamic modeling of activity of ceftazidime during continuous and intermittent infusion. Antimicrob. Agents Chemother. 41:733-738.
18. Mueller, M., A. de la Pena, and H. Derendorf. 2004. Issues in pharmacokinetics and pharmacodynamics of anti-infective agents: kill curves versus MIC. Antimicrob. Agents Chemother. 48:369-377.
19. NCCLS. 2003. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 6th ed. Document M7-A6. NCCLS, Villanova, PA.
20. Regoes, R. R., C. Wiuff, R. M. Zappala, K. N. Garner, F. Baquero, and B. R. Levin. 2004. Pharmacodynamic functions: a multiparameter approach to the design of antibiotic treatment regimens. Antimicrob. Agents Chemother. 48:3670-3676.
21. Schuck, E. L., and H. Derendorf. 2005. Pharmacokinetic/ pharmacodynamic evaluation of anti-infective agents. Expert Rev. Anti-Infect. Ther. 3:361-373.
22. Sheiner, L. B., D. R. Stanski, S. Vozeh, R. D. Miller, and J. Ham. 1979. Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin. Pharmacol. Ther. 25:358-371.
23. Tan, V. H., A. N. Schilling, and M. Nikolaou. 2005. Modelling time-kill studies to discern the pharmacodynamics of meropenem. J. Antimicrob. Chemother. 55:699-706.
24. Yano, Y., T. Oguma, H. Nagata, and S. Sasaki. 1998. Application of logistic growth model to pharmacodynamic analysis of in vitro bactericidal kinetics. J. Pharm. Sci. 87:1177-1183.
25. Zhi, J., C. H. Nightingale, and R. Quintiliani. 1986. A pharmacodynamic model for the activity of antibiotics against microorganisms under nonsaturable conditions. J. Pharm. Sci. 75:1063-1067.